Last $160.87 USD
Change Today +1.06 / 0.66%
Volume 1.1M
AMGN On Other Exchanges
Symbol
Exchange
Hong Kong
Mexico
NASDAQ GS
Sao Paulo
Frankfurt
As of 12:00 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Open
$159.62
Previous Close
$159.81
Day High
$161.48
Day Low
$157.67
52 Week High
12/8/14 - $173.14
52 Week Low
04/28/14 - $108.20
Market Cap
122.4B
Average Volume 10 Days
3.4M
EPS TTM
$6.75
Shares Outstanding
760.7M
EX-Date
02/10/15
P/E TM
23.8x
Dividend
$3.16
Dividend Yield
1.52%
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company’s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company’s products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

20,000 Employees
Last Reported Date: 02/24/14
Founded in 1980

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Executive Vice President of Operations
Total Annual Compensation: $1.1M
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Executive Vice President of Research & Develo...
Total Annual Compensation: $896.5K
Compensation as of Fiscal Year 2013.

amgen inc (AMGN) Key Developments

Nantcell Enters into Licensing Agreement with Amgen Inc. for Amg 479

NantCell has entered into a licensing agreement with Amgen for AMG 479 (ganitumab), previously in Phase 3 development. under the agreement, NantCell acquired the exclusive rights to develop and commercialize worldwide, excluding Japan, AMG 479, a fully human monoclonal antibody that targets Type 1 insulin-like growth factor receptor (IGF-1R), a promising target for cancer therapy. Financial terms were not disclosed.

Amgen Inc. Presents New Data Supporting First-Line Use of Vectibix® (Panitumumab) in Combination with Folfox in Patients with Wild-Type RAS Metastatic Colorectal Cancer

Amgen announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, in patients with wild-type RAS (absence of exons 2, 3, or 4 KRAS or NRAS mutations) metastatic colorectal cancer (mCRC). The data will be presented during a poster session at the 2015 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place in San Francisco from January 15 to 17. In an exploratory analysis from the PEAK study (abstract #660), treatment with Vectibix compared to bevacizumab (Avastin) resulted in a significantly higher proportion of patients with earlier tumor shrinkage at week eight (64 % vs. 45 %, respectively; 95 % CI, p=0.0232), and among responding patients, a significantly longer duration of response (11.4 vs. 8.5 months, respectively; 95% CI, p=0.0142) and greater depth of response (65 % vs. 46%, respectively; p=0.0007). Overall response rates (ORR) appeared to be similar between Vectibix and bevacizumab. This is consistent with observed overall survival (OS) and progression-free survival (PFS) rates, and with data previously reported. The safety profile of Vectibix was consistent with previously reported studies. While the primary analysis from PEAK showed similar ORR between the Vectibix- and bevacizumab-based regimens, this exploratory analysis demonstrates that Vectibix produces early, sustained anti-tumor activity, which may in part explain the OS and PFS benefits seen with Vectibix versus bevacizumab in this trial. A separate analysis from the Phase 3 PRIME study (abstract #537), demonstrated that there were no significant differences in quality of life among patients treated with Vectibix plus FOLFOX versus FOLFOX alone despite the incidence of adverse events associated with each treatment regimen. The quality of life analysis included a scale that assessed mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

NantCell, LLC Enters into a Licensing Agreement with Amgen Inc. for an Oncology Antibody

NantCell, LLC announced that it has entered into a licensing agreement with Amgen Inc. for AMG 479 (ganitumab), previously in Phase 3 development. Under the agreement, NantCell acquired the exclusive rights to develop and commercialize worldwide, excluding Japan, AMG 479, a fully human monoclonal antibody that targets Type 1 insulin-like growth factor receptor (IGF-1R), a promising target for cancer therapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $160.79 USD +0.98

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $162.40 USD -1.62
AbbVie Inc $62.77 USD +0.335
Eli Lilly & Co $72.11 USD -0.02
Gilead Sciences Inc $107.25 USD +1.71
Novo Nordisk A/S kr297.20 DKK +4.20
View Industry Companies
 

Industry Analysis

AMGN

Industry Average

Valuation AMGN Industry Range
Price/Earnings 25.1x
Price/Sales 6.2x
Price/Book 4.8x
Price/Cash Flow 24.9x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit www.amgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.